The risk of developing a blood clot occurs in up to 60% of all critical care patients. Many
times enoxaparin (or Lovenox®) is given to patients who are at a higher risk of developing
clots in their legs or lungs. Recent data suggest that a standard dose of Lovenox may not
fully prevent the development of these clots especially in critically ill or obese patients.
Routine enoxaparin dosing can also result in bleeding complications. Thrombelastography
(TEG®) can be used to measure how blood clots. The purposes of this study are:
- to learn if the TEG® can better guide physicians in prescribing an effective dose of
Lovenox compared to standard doses recommended by the drug company in preventing blood
clots from developing in the legs and lungs, and
- to compare the development of blood clots in patients receiving the standard dose of
enoxaparin compared to patients receiving a TEG® guided dose of enoxaparin.
- to determine if TEG guided dosing results in decreased bleeding complications compared
to standard dosing.
Phase:
N/A
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
Medical Research Foundation, Oregon National Trauma Institute National Trauma Research Institute